Department of Endocrinology, Huaian First Hospital Affiliated to Nanjing Medical University, Huaian, PR China.
Kidney Blood Press Res. 2012;35(6):483-8. doi: 10.1159/000337929. Epub 2012 Jun 8.
It was reported that exenatide ameliorated renal injury in diabetic rats. The present study was carried out to evaluate the effect of exenatide on 24-hour urinary albumin, urinary transforming growth factor-β(1) (TGF-β(1)) and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria.
31 type 2 diabetic patients with microalbuminuria were randomly allocated to receive exenatide (group Exe, n = 13) or glimepiride treatment (group Glm, n = 18) for 16 weeks. Body mass index (BMI), fasting plasma glucose, 2-hour postprandial plasma glucose, glycated hemoglobin A(1c), systolic blood pressure, diastolic blood pressure, 24-hour urinary albumin, urinary TGF-β(1) and type IV collagen concentration were analyzed between the two treatment groups. 20 age- and BMI-matched healthy subjects were chosen as the normal control group (group NC, n = 20).
After 16 weeks of treatment, 24-hour urinary albumin, urinary TGF-β(1) and type IV collagen in group Exe were significantly lower than those of group Glm (p < 0.01), while glycemic control had no statistical difference between the two groups.
Our results indicate that exenatide reduces urinary TGF-β(1) and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria, which may be partly contributory to its directly renoprotective role.
有报道称艾塞那肽可改善糖尿病大鼠的肾损伤。本研究旨在评估艾塞那肽对 2 型糖尿病伴微量白蛋白尿患者 24 小时尿白蛋白、尿转化生长因子-β1（TGF-β1）和Ⅳ型胶原排泄的影响。
31 例 2 型糖尿病伴微量白蛋白尿患者被随机分为艾塞那肽（Exe 组，n = 13）或格列美脲（Glm 组，n = 18）治疗 16 周。分析两组患者的体重指数（BMI）、空腹血糖、餐后 2 小时血糖、糖化血红蛋白 A1c、收缩压、舒张压、24 小时尿白蛋白、尿 TGF-β1 和Ⅳ型胶原浓度。选择 20 例年龄和 BMI 匹配的健康人作为正常对照组（NC 组，n = 20）。
治疗 16 周后，Exe 组 24 小时尿白蛋白、尿 TGF-β1 和Ⅳ型胶原均明显低于 Glm 组（p < 0.01），而两组间血糖控制无统计学差异。
我们的结果表明，艾塞那肽可降低 2 型糖尿病伴微量白蛋白尿患者尿 TGF-β1 和Ⅳ型胶原排泄，这可能与其直接的肾脏保护作用部分相关。
